Rocuronium clinical trials
Rocuronium is named as an intervention in 5 current clinical trials in our Turkey, China, Denmark and Poland registers. 3 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Jiangsu HengRui Medicine Co., Ltd (1). The most-studied condition is Neuromuscular Blockade. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Rocuronium is approved
All regulators →Of the three regulators tracked here, the first to approve Rocuronium was the US, on 17 Mar 1994. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Rocuronium patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Rocuronium, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 1 listed patent; the last listed expires 22 Jul 2039 (US 11998605).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Rocuronium
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Rocuronium works
All drug targets →- Muscle-type nicotinic acetylcholine receptor antagonist AntagonistTarget: Muscle-type nicotinic acetylcholine receptorChEMBL only
- Cardiac arrestPhase 3
- PainPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201244, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 4003, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Rocuronium
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 8 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Rocuronium
- ATC code
- M03AC09
- ChEMBL
- CHEMBL1201244
- DrugBank
- DB00728
- PubChem CID
- 441290
- CAS number
- 143558-00-3
- FDA UNII
- WRE554RFEZ
- Wikidata
- Q185331
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Rocuronium
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Rocuronium in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Rocuronium. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Rapid sequence emergence of general Anaesthesia
2024-516415-24-03 · CTIS ↗ · Anesthesia and Analgesia
|
Phase 4 | Authorised | Stichting Radboud universitair medisch centrum | Netherlands |
Rocuronium across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
8 single-substance products containing Rocuronium on the HPRA medicines list.
- Rocuronium 10 mg/ml solution for injection/infusionB. Braun Melsungen AG · PA0736/029/001 · Marketed
- Rocuronium 10 mg/ml solution for injection/infusionFresenius Kabi Deutschland GmbH · PA2059/018/001 · Marketed
- Rocuronium Bromide 10 mg/ml solution for Injection/InfusionIbigen Srl · PA1862/001/001 · Marketed
- Rocuronium bromide 10 mg/mL solution for injection in pre-filled syringeLaboratoire Aguettant · PA1968/015/001 · Marketed
- Rocuronium bromide 10 mg/ml solution for injection/infusionAS Kalceks · PA2165/004/001 · Marketed
Supply shortages
- Rocuronium Bromide InjectionUS (FDA) · Current · updated 3 Nov 2026
Conditions studied with Rocuronium
16 conditionsAll 16 conditions
| Condition (as registered) | Trials |
|---|---|
| Neuromuscular Blockade | 1 |
| Tracheal Intubation | 1 |
| Video Laryngoscopy | 1 |
| Remifentanil | 1 |
| Rocuronium | 1 |
| Kidney Failure, Acute | 1 |
| Myopathy; Drugs | 1 |
| Heart Arrhythmia | 1 |
| Succinylcholine Sensitivity | 1 |
| Driving Pressure | 1 |
| Neuromuscular Blockade Monitoring | 1 |
| Postoperative Respiratory Complications | 1 |
| Airway Management | 1 |
| Supraglottic Airway Device Insertion | 1 |
| Laryngeal Mask Airways | 1 |
| Anesthesia, General | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd | 1 |
| Nordsjaellands Hospital | 1 |
| 4th Military Clinical Hospital with Polyclinic, Poland | 1 |
| Ankara City Hospital Bilkent | 1 |
| Hacettepe University | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Turkey | 2 | 0 |
| Clinical trials in China | 1 | 1 |
| Clinical trials in Denmark | 1 | 1 |
| Clinical trials in Poland | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Rocuronium trials
How many clinical trials are testing Rocuronium?
5 current trials in our Turkey, China, Denmark and Poland registers name Rocuronium as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Rocuronium trials recruiting patients?
Yes. 3 of the 5 trials are recruiting: 1 with sites in China, 1 with sites in Denmark and 1 with sites in Poland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Rocuronium clinical trials?
Jiangsu HengRui Medicine Co., Ltd (1), Nordsjaellands Hospital (1), 4th Military Clinical Hospital with Polyclinic, Poland (1) and Ankara City Hospital Bilkent (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Rocuronium licensed in Ireland?
Yes. The HPRA medicines list includes 8 single-substance products containing Rocuronium, for example Rocuronium 10 mg/ml solution for injection/infusion (B. Braun Melsungen AG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Rocuronium shortage?
The registers we track list 1 entry for Rocuronium: US FDA: current. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rocuronium works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rocuronium works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rocuronium (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.